In preclinical BrCa models, GEM has been deemed a myeloablative therapy, as it significantly reduces the presence of GR-1+ MDSCs [40] in the periphery of tumor-bearing mice without perturbing other immune cell populations like CD4+ T cells, CD8+ T cells, and B cells [41,42]. This evidence concerns the gene CD4 and neoplasm.